Cited by 89Inflammatory Biomarkers in Disease PrognosisCancer Risks and FactorsBreast Cancer Treatment Studies

Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study

Open access

Abstract

Background: Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors. Methods: The Women's Healthy Eating and Living Study includes 2,919 early-stage breast cancer survivors with serum collected 2 years postdiagnosis and follow-up for clinical outcomes over approximately 7 years. CRP concentrations were measured using high-sensitivity electrochemiluminescence assay. Outcomes, including all-cause mortality, breast cancer–specific mortality, and additional breast cancer events were oncologist verified from medical records and death certificates. Cox proportional hazards models were conducted with adjustment for potential confounding factors to generate HRs and 95% confidence intervals (CI). Results: CRP concentrations in women diagnosed with breast cancer were associated with death due to any cause, death due to breast cancer, and additional breast cancer events, after adjustment for sociodemographic and cancer characteristics (lnCRP: P < 0.05 for all three outcomes). The HR for women with (vs. without) acute inflammation suggests a threshold effect on overall survival, rather than a dose–response relationship (≥10.0 mg/L vs. <1 mg/L: HR, 1.96; 95% CI, 1.22–3.13). Associations were similar for breast cancer–specific mortality (HR, 1.91; 95% CI, 1.13–3.23) and any additional breast cancer–related event (HR, 1.69; 95% CI, 1.17–2.43). Conclusions: Acute inflammation status (CRP ≥ 10 mg/L) may be an important independent biomarker for long-term survival in breast cancer survivors. Impact: Interventions to decrease circulating CRP concentrations in breast cancer survivors with acute inflammation may improve prognosis. Cancer Epidemiol Biomarkers Prev; 23(1); 189–99. ©2013 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-13-0852

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Villaseñor, A., Flatt, S. W., Marinac, C., Natarajan, L., Pierce, J. P., & Patterson, R. E.
Affiliations
University of California San Diego (US)
Corresponding author
Patterson, Ruth E.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2014-01-01
Volume
23
Issue
1
Pages
189-199
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2169510064
Cited by
89
References
39
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 19 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 6 · 2015: 8 · 2014: 6
FWCI
3.55
Type
journal article
Language
en
Open access
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (5m01rr000079-42, 1t32gm084896-01)
  • National Cancer Institute (5R01 CA69375-10, R01CA166293, P30CA023100, R01CA069375)
  • National Institute of General Medical Sciences (T32-GM084896, 5 T32GM084896)
  • National Center for Research Resources (M01-RR000079, M01RR000070, M01 RR-00079, M01RR000827)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
C-reactive protein, breast cancer survivors, acute inflammation, inflammatory markers, all-cause mortality, breast cancer-specific mortality, breast cancer recurrence, long-term survival, prognostic factors
MeSH terms
Adult, Aged, Breast Neoplasms, C-Reactive Protein, Female, Humans, Middle Aged, Prognosis, United States, Cohort Studies, Randomized Controlled Trials as Topic, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review